Literature DB >> 16296413

[Focal segmental glomerulosclerosis in a patient with polycythemia vera].

Masayuki Iyoda1, Jyun Ito, Yuriko Ajiro, Hisako Nagai, Junichi Uchida, Hirokazu Honda, Aki Kuroki, Takanori Shibata, Kozo Kitazawa, Tetsuzo Sugisaki.   

Abstract

Herein we describe the case of a patient with focal segmental glomerulosclerosis (FSGS) following polycythemia vera (PV) on whom hemodialysis was started 7 years later. A 66-year-old woman who had been treated for PV with hydroxyurea and phlebotomy for three years was referred to our hospital because of nephrotic syndrome. Renal biopsy performed at her local hospital revealed FSGS. Although she had received prednisolone at an initial dose of 45 mg/day, no significant improvement of proteinuria was achieved. The dose of prednisolone was tapered because the second renal biopsy revealed sclerosing glomerulopathy. We considered that FSGS was associated with PV because renal hemodynamic alterations in PV could result in FSGS as in any other secondary FSGS and there was no proteinuria at the initial detection of PV. On January 29, 1999, she developed massive proteinuria (9.6 g/day) and the findings of the third renal biopsy worsened in comparison with that of the first renal biopsy. Thereafter, hydroxyurea or ranimustine was used in treating PV at an outpatient clinic. However severe thrombocytosis was difficult to control, and progressive renal dysfunction finally necessitated hemodialysis on January 18, 2005. In conclusion, physicians should be aware of the risk of progressive renal failure in patients with FSGS following PV, particularly in patients with persistent thrombocytosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16296413

Source DB:  PubMed          Journal:  Nihon Jinzo Gakkai Shi        ISSN: 0385-2385


  1 in total

1.  Polycythemia vera associated with IgA nephropathy: A case report and literature review.

Authors:  Hong Chen; Baohe Zhang; Mingxu Li; Ruilan Hu; Chunhua Zhou
Journal:  Exp Ther Med       Date:  2015-06-11       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.